Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
893
datasets available to search
ShareScore release 0.9.0
Dataset results
893 results for “anti-tumor”
A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies
ClinicalTrials.gov study NCT03888105. IPD Sharing: YES. Countries: 14. Publications: 3.
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor
ClinicalTrials.gov study NCT01350804. IPD Sharing: Not stated. Countries: 15. Publications: 2.
Data from: DGKα/ζ inhibition lowers the TCR affinity threshold and potentiates anti-tumor immunity
Open the record for dataset details and reuse information.
YY1 enhances HIF-1α stability in tumor-associated macrophages to suppress anti-tumor immunity of prostate cancer
Open the record for dataset details and reuse information.
BAF155 Methylation Drives Metastasis By Hijacking Super-enhancers and Subverting Anti-tumor Immunity
Open the record for dataset details and reuse information.
ARID1A suppresses R-loop mediated STING-Type I Interferon pathway activation of anti-tumor immunity
<p>Clinical trials have identified ARID1A mutations as enriched among patients who respond favorably to Immune Checkpoint Blockade (ICB) in several solid tumor types independent of microsatellite instability. We show that ARID1A loss in murine models is sufficient to induce anti-tumor immune phenotypes observed in ARID1A mutant human cancers, including increased CD8+ T cell infiltration and cytolytic activity. ARID1A deficient cancers upregulated an interferon (IFN) gene expression signature, the ARID1A-IFN signature, associated with increased R-loops and cytosolic single stranded DNA (ssDNA). Overexpression of the R-loop resolving enzyme, RNASEH2B, or cytosolic DNase, TREX1, in ARID1A deficient cells prevented cytosolic ssDNA accumulation and ARID1A-IFN gene upregulation. Further, the ARID1A-IFN signature and anti-tumor immunity were driven by STING dependent Type I IFN signaling, which was required for improved responsiveness of ARID1A mutant tumors to ICB treatment. These findings define a molecular mechanism underlying anti-tumor immunity in ARID1A mutant cancers.</p>
Fig. 2. Key 1 H– 1 H in Pimarane, abietane, and labdane diterpenoids from Euphorbia pekinensis Rupr. and their anti-tumor activities
Fig. 2. Key 1 H– 1 H COSY (red bold lines) and HMBC (blue→) of compounds 5 (a1) and 16 (a2), NOSEY correlation (blue→) of compounds 5 (b1) and 16 (b2), The ORTEP drawing of compounds 5 (c1) and 16 (c2). (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)
Fig. 3. Key 1H–1H in Pimarane, abietane, and labdane diterpenoids from Euphorbia pekinensis Rupr. and their anti-tumor activities
Fig. 3. Key 1H–1H COSY (red bold lines) and HMBC (blue→) of compound 9 (a), NOSEY correlation (blue→) of compound 9 (b), The ORTEP drawing of compound 9 (c). (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)
Fig. 4. Key 1H–1H in Pimarane, abietane, and labdane diterpenoids from Euphorbia pekinensis Rupr. and their anti-tumor activities
Fig. 4. Key 1H–1H COSY (red bold lines) and HMBC (blue→) correlation of compounds 11 (a), 12 (b), 13 (c), and 15 (d). (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)
Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular Carcinoma
ClinicalTrials.gov study NCT02191878. IPD Sharing: Not stated. Countries: 6. Publications: 1.
To Observe the Impacts of Anti-Tumor Necrosis Factor (TNF) Effectiveness on Improvement in Work Place and Household Productivity for Patients With Psoriatic Arthritis (PsA)
ClinicalTrials.gov study NCT02028169. IPD Sharing: Not stated. Countries: 0. Publications: 1.
A Study of Guselkumab in Participants With Active Psoriatic Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Alpha (Anti-TNF Alpha) Therapy
ClinicalTrials.gov study NCT03796858. IPD Sharing: YES. Countries: 14. Publications: 7.
Phase I Study to Evaluate Safety and Anti-tumor Activity of PB101, an Anti-angiogenic Immunomodulating Agent
ClinicalTrials.gov study NCT06075849. IPD Sharing: NO. Countries: 1. Publications: 2.
A Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects With Advanced Solid Tumors Likely to Express Prolactin Receptor (PRLR)
ClinicalTrials.gov study NCT03145909. IPD Sharing: UNDECIDED. Countries: 4. Publications: 1.
Recombinant Anti-tumor and Anti-virus Protein for Injection in Treatment of Metastatic Colorectal Cancer
ClinicalTrials.gov study NCT01386242. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Study to Evaluate the Safety and Anti-tumor Activity of SNK01 (NK Cells) Administered in Combination With Chemotherapy or Chemotherapy / Cetuximab in Local Advanced or Metastatic Non-small Cell Lung
ClinicalTrials.gov study NCT04872634. IPD Sharing: NO. Countries: 1. Publications: 1.
A Study to Evaluate Safety, Pharmacokinetics and Anti-Tumor Activity of RO7300490, as Single Agent or in Combination With Atezolizumab in Participants With Advanced Solid Tumors
ClinicalTrials.gov study NCT04857138. IPD Sharing: Not stated. Countries: 5. Publications: 0.
Sub-optimal Response to Anti-Tumor Necrosis Factor's in Inflammatory Bowel Disease in Emerging Markets
ClinicalTrials.gov study NCT03090139. IPD Sharing: Not stated. Countries: 10. Publications: 2.
Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer
ClinicalTrials.gov study NCT04270591. IPD Sharing: NO. Countries: 3. Publications: 11.
Study To Evaluate Safety, Pharmacokinetics, Pharmacodynamics, And Preliminary Anti-Tumor Activity Of RO7122290 In Combination With Cibisatamab With Obinutuzumab Pre-Treatment
ClinicalTrials.gov study NCT04826003. IPD Sharing: Not stated. Countries: 5. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.